Oruka Therapeutics, Inc. $ORKA Shares Newly Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the third quarter, Holdings Channel.com reports. The firm purchased 13,996 shares of the company’s stock, valued at approximately $1,166,000.

Several other hedge funds have also recently made changes to their positions in the stock. Nykredit A S bought a new position in Oruka Therapeutics during the second quarter valued at approximately $29,000. GAMMA Investing LLC boosted its holdings in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics in the second quarter worth approximately $91,000. Sterling Capital Management LLC grew its position in Oruka Therapeutics by 839.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after purchasing an additional 1,485 shares during the period. Finally, Natural Investments LLC bought a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $202,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $104.99 on Friday. The firm has a 50 day moving average of $89.39 and a 200 day moving average of $72.01. Oruka Therapeutics, Inc. has a 12-month low of $25.23 and a 12-month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). Analysts anticipate that Oruka Therapeutics, Inc. will post -2.50 earnings per share for the current year.

Key Headlines Impacting Oruka Therapeutics

These are some of the ORKA headlines that stood out recently:

• Neutral Sentiment: Phase 2 psoriasis results could be a significant upcoming catalyst for the stock, but the article does not report new trial results. Phase 2 psoriasis results article
• Negative Sentiment: HC Wainwright lowered its quarterly and full-year EPS estimates through 2027, including its FY2027 forecast from a loss of $2.82 to a loss of $3.22 per share. The analyst maintained a Buy rating, but the deeper projected losses may weigh on sentiment.
• Negative Sentiment: A newly disclosed patent-expiry risk could expose Oruka to earlier generic competition and pressure future revenue. Patent-expiry risk article

Analyst Ratings Changes

ORKA has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Wedbush restated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. Finally, Guggenheim reiterated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research report on Monday, October 26th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $141.80.

Insider Activity

In other news, CEO Lawrence Klein sold 25,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $95.60, for a total value of $2,390,000.00. Following the completion of the sale, the chief executive officer directly owned 923,128 shares in the company, valued at $88,251,036.80. This represents a 2.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the completion of the sale, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 169,950 shares of company stock valued at $15,426,080 in the last 90 days. Company insiders own 23.49% of the company’s stock.

Oruka Therapeutics Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.